Pioneer Group has announced its successful exit from Alderley Analytical, a leading independent contract research organisation (CRO) specialising in bioanalytical services, following the company’s acquisition by Synexa Life Sciences Ltd, a Dutch-based company backed by major European healthcare investor Gilde Healthcare.
Founded in 2013, Alderley Analytical offers a full range of bioanalytical services to support discovery, pre-clinical and clinical drug development projects in small molecules, large molecules, peptides, oligonucleotides and biomarkers. It recently moved to a state-of-the-art laboratory near Manchester and is GLP/GCP accredited.
Alderley Park Ventures, the seed investment fund managed by Pioneer Group, was the very first investor in Alderley Analytical. The investment came following the company’s participation in Pioneer’s Accelerator Programme at Alderley Park.
Dr Glenn Crocker, Executive Director of Pioneer Group, commented: “We’re delighted that Alderley Analytical’s leading bioanalytical capabilities have been recognised through its acquisition by Synexa. Our exit represents yet another good return from a Pioneer investment portfolio company, with Alderley Park Ventures having been the first investor in Alderley Analytical.
“Since then, the company has grown significantly and now employs 60 staff members. This acquisition will enable Alderley Analytical to expand its presence at its new site in Macclesfield and reach a wider customer base. It’s an ideal time for the company to enter this next growth phase, and we look forward to seeing it progress as part of the Synexa family.”
Paul Holme, Co-Founder and Director of Alderley Analytical, said: “As we enter this new phase with Synexa Life Sciences, we’re grateful for the early support from Pioneer Group. Pioneer’s investment and advice allowed us to build a company that delivers high-quality, bespoke bioanalytical services to pharmaceutical, biotech, and CRO clients worldwide.
“Becoming a part of the Synexa Group is a fantastic next step for our business which will allow us to accelerate our growth plan. Both parties in this acquisition will bring a valued opportunity to each business. There is a strong strategic rationale in bringing Alderley Analytical and Synexa together with many commercial synergies already identified.”
Pictured above: Alderley Analytical co-founders: Sally Hannam, Claire Wildgoose, and Paul Holme.